Top

BMC Nephrology

Published in:

Open Access 01-12-2021 | Peritoneal Dialysis | Guidelines

Commentary on the NICE guideline on renal replacement therapy and conservative management

Authors: Kunaal Kharbanda, Osasuyi Iyasere, Fergus Caskey, Matko Marlais, Sandip Mitra

Published in: BMC Nephrology | Issue 1/2021

Abstract

Background

NICE Guideline NG107, “Renal replacement therapy and conservative management” (Renal replacement therapy and conservative management (NG107); 2018:1–33) was published in October 2018 and replaced the existing NICE guideline CG125, “Chronic Kidney Disease (Stage 5): peritoneal dialysis” (Chronic kidney disease (stage 5): peritoneal dialysis | Guidance | NICE; 2011) and NICE Technology Appraisal TA48, “Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure”(Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (Technology appraisal guideline TA48); 2002) The aim of the NICE guideline (NG107) was to provide guidance on renal replacement therapy (RRT), including dialysis, transplant and conservative care, for adults and children with CKD Stages 4 and 5. The guideline is extremely welcomed by the Renal Association and it offers huge value to patients, clinicians, commissioners and key stakeholders. It overlaps and enhances current guidance published by the Renal Association including “Haemodialysis” (Clinical practice guideline: Haemodialysis; 2019) which was updated in 2019 after the publication of the NICE guideline, “Peritoneal Dialysis in Adults and Children” (Clinical practice guideline: peritoneal Dialysis in adults and children; 2017) and “Planning, Initiation & withdrawal of Renal Replacement Therapy” (Clinical practice guideline: planning, initiation and withdrawal of renal replacement therapy; 2014) (at present there are no plans to update this guideline).

There are several strengths to NICE guideline NG107 and we agree with and support the vast majority of recommendation statements in the guideline. This summary from the Renal Association discusses some of the key highlights, controversies, gaps in knowledge and challenges in implementation. Where there is disagreement with a NICE guideline statement, we have highlighted this and a new suggested statement has been written.

Preka E, Bonthuis M, Harambat J, Jager KJ, Groothoff JW, Baiko S, et al. Association between timing of dialysis initiation and clinical outcomes in the paediatric population: an ESPN/ERA-EDTA registry study. Nephrol Dialysis Transplant. 2019;34(11):1932–40. https://doi.org/10.1093/ndt/gfz069.CrossRef

Chan CT, Blankestijn PJ, Dember LM, Gallieni M, Harris DCH, Lok CE, et al. Dialysis initiation, modality choice, access, and prescription: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019 Jul 1;96(1):37–47. https://doi.org/10.1016/j.kint.2019.01.017.CrossRefPubMed

Stack AG, Martin DR. Association of patient autonomy with increased transplantation and survival among new dialysis patients in the United States. Am J Kidney Dis. 2005 Apr;45(4):730–42. https://doi.org/10.1053/j.ajkd.2004.12.016.CrossRefPubMed

Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012 Mar;23(3):533–44. https://doi.org/10.1681/ASN.2011060607.CrossRefPubMedPubMedCentral

MacNeill SJ, Ford D, Evans K, Medcalf JF. Chapter 2 UK renal replacement therapy adult prevalence in 2016: national and Centre-specific analyses. Nephron. 2018;139(Suppl 1):47–74. https://doi.org/10.1159/000490960.CrossRefPubMed

Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int. 1999;19(6):526–33. https://doi.org/10.1177/089686089901900606.CrossRefPubMed

de Fijter CW, Oe LP, Nauta JJ, van der Meulen J, Verbrugh HA, Verhoef J, et al. Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med. 1994 Feb 15;120(4):264–71. https://doi.org/10.7326/0003-4819-120-4-199402150-00002.CrossRefPubMed

Li PK-T, Szeto C-C, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016 Sep 10;36(5):481–508. https://doi.org/10.3747/pdi.2016.00078.CrossRefPubMedPubMedCentral

Iyasere O, Brown E, Gordon F, Collinson H, Fielding R, Fluck R, et al. Longitudinal trends in quality of life and physical function in frail older Dialysis patients: a comparison of assisted peritoneal Dialysis and in-center hemodialysis. Perit Dial Int. 2019 Mar;39(2):112–8. https://doi.org/10.3747/pdi.2018.00086.CrossRefPubMed

10.

Oliver MJ, Al-Jaishi AA, Dixon SN, Perl J, Jain AK, Lavoie SD, et al. Hospitalization rates for patients on assisted peritoneal Dialysis compared with in-center hemodialysis. Clin J Am Soc Nephrol. 2016;11(9):1606–14. https://doi.org/10.2215/CJN.10130915.CrossRefPubMedPubMedCentral

11.

Griva K, Goh CS, Kang WCA, Yu ZL, Chan MC, Wu SY, et al. Quality of life and emotional distress in patients and burden in caregivers: a comparison between assisted peritoneal dialysis and self-care peritoneal dialysis. Qual Life Res. 2016 Feb;25(2):373–84. https://doi.org/10.1007/s11136-015-1074-8.CrossRefPubMed

12.

Lobbedez T, Verger C, Ryckelynck J-P, Fabre E, Evans D. Is assisted peritoneal dialysis associated with technique survival when competing events are considered? Clin J Am Soc Nephrol. 2012;7(4):612–8.

13.

Guilloteau S, Lobbedez T, Guillouët S, Verger C, Ficheux M, Lanot A, et al. Impact of assisted peritoneal Dialysis modality on outcomes: a cohort study of the French language peritoneal Dialysis registry. Am J Nephrol. 2018;48(6):425–33. https://doi.org/10.1159/000494664.CrossRefPubMed

14.

Plumb L, Wong E, Casula A, Braddon F, Lewis M, Marks SD, et al. Chapter 4 demography of the UK Paediatric renal replacement therapy population in 2016. Nephron. 2018;139(Suppl 1):105–16. https://doi.org/10.1159/000490962.CrossRefPubMed

15.

Watson AR, Hayes WN, Vondrak K, Ariceta G, Schmitt CP, Ekim M, et al. Factors influencing choice of renal replacement therapy in European paediatric nephrology units. Pediatr Nephrol. 2013;28(12):2361–8. https://doi.org/10.1007/s00467-013-2555-z.CrossRefPubMed

16.

Pyart R, Evans KM, Steenkamp R, Casula A, Wong E, Magadi W, et al. The 21st UK Renal Registry Annual Report: A Summary of Analyses of Adult Data in 2017. http://www.renal.org/audit-research/annual-report/21st-annualreport-data-31122017.

17.

Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess. 2003;7(2):1–174. https://doi.org/10.3310/hta7020.CrossRefPubMed

18.

Klarenbach S, Tonelli M, Pauly R, Walsh M, Culleton B, So H, et al. Economic evaluation of frequent home nocturnal hemodialysis based on a randomized controlled trial. J Am Soc Nephrol. 2014 Mar;25(3):587–94. https://doi.org/10.1681/ASN.2013040360.CrossRefPubMed

19.

Komenda P, Gavaghan MB, Garfield SS, Poret AW, Sood MM. An economic assessment model for in-center, conventional home, and more frequent home hemodialysis. Kidney Int. 2011 Oct 12;81:307–13.CrossRef

20.

McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int. 2002;62(6):2216–22. https://doi.org/10.1046/j.1523-1755.2002.00678.x.CrossRefPubMed

21.

Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting--a multicentre study. Nephrol Dial Transplant. 2008 Jun;23(6):1982–9. https://doi.org/10.1093/ndt/gfm870.CrossRefPubMed

22.

Krahn MD, Bremner KE, de Oliveira C, Dixon SN, McFarlane P, Garg AX, et al. Home Dialysis is associated with lower costs and better survival than other modalities: a population-based study in Ontario, Canada. Perit Dial Int. 2019 Nov;39(6):553–61. https://doi.org/10.3747/pdi.2018.00268.CrossRefPubMed

23.

Wong CKH, Chen J, Fung SKS, Mok MMY, Cheng YL, Kong I, et al. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2019 Sep 1;34(9):1565–76. https://doi.org/10.1093/ndt/gfy395.CrossRefPubMed

24.

Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007 Sep 19;298(11):1291–9. https://doi.org/10.1001/jama.298.11.1291.CrossRefPubMed

25.

Graham-Brown MPM, Churchward DR, Hull KL, Preston R, Pickering WP, Eborall HC, et al. Cardiac Remodelling in patients undergoing in-Centre nocturnal Haemodialysis: results from the MIDNIGHT study, a non-randomized controlled trial. Blood Purif. 2017;44(4):301–10. https://doi.org/10.1159/000481248.CrossRefPubMed

26.

Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension. 2003 Nov;42(5):925–31. https://doi.org/10.1161/01.HYP.0000097605.35343.64.CrossRefPubMed

27.

Fagugli RM, Pasini P, Pasticci F, Ciao G, Cicconi B, Buoncristiani U. Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J Nephrol. 2006 Jan;19(1):77–83.PubMed

28.

Al-Hejaili F. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol. 2003;14(9):2322–8. https://doi.org/10.1097/01.ASN.0000083044.42480.C1.CrossRefPubMed

29.

Ok E, Duman S, Asci G, Tumuklu M, Onen Sertoz O, Kayikcioglu M, et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-Centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant. 2011 Apr;26(4):1287–96. https://doi.org/10.1093/ndt/gfq724.CrossRefPubMed

30.

Johansen KL, Zhang R, Huang Y, Chen S-C, Blagg CR, Goldfarb-Rumyantzev AS, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int. 2009 Nov;76(9):984–90. https://doi.org/10.1038/ki.2009.291.CrossRefPubMedPubMedCentral

31.

Woods JD, Port FK, Stannard D, Blagg CR, Held PJ. Comparison of mortality with home hemodialysis and center hemodialysis: a national study. Kidney Int. 1996 Jan 1;49(5):1464–70. https://doi.org/10.1038/ki.1996.206.CrossRefPubMed

32.

Marshall MR, HAWLEY CM, Kerr PG, Polkinghorne KR, Marshall RJ, Agar JWM, et al. Home hemodialysis and mortality risk in Australian and New Zealand populations. Am J Kidney Dis. 2011;58(5):782–93. https://doi.org/10.1053/j.ajkd.2011.04.027.CrossRefPubMed

33.

Keating PT, Walsh M, Ribic CM, Brimble KS. The impact of patient preference on dialysis modality and hemodialysis vascular access. BMC Nephrol. 2014;15:1.CrossRef

34.

Blake PG, Quinn RR, Oliver MJ. Peritoneal dialysis and the process of modality selection. Perit Dial Int. 2013 May;33(3):233–41. https://doi.org/10.3747/pdi.2012.00119.CrossRefPubMedPubMedCentral

35.

Kharbanda K, Dutton G, Woods J, Mitra S. A Single Centre 3 year Experience of Implementing On-line Haemodiafiltration At Home (17UKKW-526 ). UK Kidney Week. 2017;19. https://renal.org/sites/renal.org/files/17UKKW-526_PO-166.pdf.

36.

Vega A, Abad S, Macías N, Aragoncillo I. On-line hemodiafiltration at home. Hemodial Int. 2018 Apr;22(2):E33–5. https://doi.org/10.1111/hdi.12609.CrossRefPubMed

37.

Hoenich NA, Mactier R, Boyle G, Harrington M, Lindley E, Rylance P, et al. Guideline on water treatment facilities, dialysis water and dialysis fluid quality for haemodialysis and related therapies; 2012. p. 1–36.

38.

Canaud B, Köhler K, Sichart J-M, Möller S. Global prevalent use, trends and practices in haemodiafiltration. Nephrol Dial Transplant. 2019;347:2068.

39.

Staff E-ER: ERA-EDTA registry annual report 2017. Amsterdam, 2019.

40.

Shroff R, Smith C, Ranchin B, Bayazit AK, Stefanidis CJ, Askiti V, et al. Effects of Hemodiafiltration versus conventional hemodialysis in children with ESKD: the HDF, heart and height study. J Am Soc Nephrol. 2019 Mar 29;30(4):678–91. https://doi.org/10.1681/ASN.2018100990.CrossRefPubMedPubMedCentral

41.

Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012 Jun;23(6):1087–96. https://doi.org/10.1681/ASN.2011121140.CrossRefPubMedPubMedCentral

42.

Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Feb;24(3):487–97. https://doi.org/10.1681/ASN.2012080875.CrossRefPubMedPubMedCentral

43.

Morena M, Jaussent A, Chalabi L, LERAY-MORAGUES H, CHENINE L, Debure A, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. Kidney Int. 2017;91(6):1495–509. https://doi.org/10.1016/j.kint.2017.01.013.CrossRefPubMed

44.

Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study. Nephrol Dial Transplant. 2013 Jan;28(1):192–202. https://doi.org/10.1093/ndt/gfs407.CrossRefPubMed

45.

Guideline Committee: Clinical practice guideline: Haemodialysis. 2019.Available from: https://renal.org/wp-content/uploads/2019/10/FINAL-HD-Guideline.pdf

46.

Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011 Feb 10;342(feb10 2):d549. https://doi.org/10.1136/bmj.d549.CrossRefPubMed

47.

Hunter JE, FSIJOS. Fixed Effects vs. Random Effects Meta-Analysis Models: Implications for Cumulative Research Knowledge. Int J Sel Assess. 2000;8(4):275–92. https://doi.org/10.1111/1468-2389.00156.CrossRef

48.

Irish GL, Chadban S, McDonald S, Clayton PA. Quantifying lead time bias when estimating patient survival in preemptive living kidney donor transplantation. Am J Transplant. 2019 Dec;19(12):3367–76. https://doi.org/10.1111/ajt.15472.CrossRefPubMed

49.

Grams ME, Massie AB, Coresh J, Segev DL. Trends in the timing of pre-emptive kidney transplantation. J Am Soc Nephrol. 2011 Sep;22(9):1615–20. https://doi.org/10.1681/ASN.2011010023.CrossRefPubMedPubMedCentral

50.

Roderick P, Rayner H, Tonkin-Crine S, Okamoto I, Eyles C, Leydon G, et al. A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure. Health Serv Delivery Res. 2015 Apr;3(12):1–186. https://doi.org/10.3310/hsdr03120.CrossRef

51.

Australian Institute of Health and Welfare. End-stage kidney disease in Australia: total incidence, 2003–2007 (full report; 12/09/2011 edition) (AIHW); 2011. p. 1–60.

52.

Hemmelgarn BR, James MT, Manns BJ, O'Hare AM, Muntner P, Ravani P, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA. 2012 Jun 20;307(23):2507–15. https://doi.org/10.1001/jama.2012.6455.CrossRefPubMed

53.

O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med. 2012 Feb;15(2):228–35. https://doi.org/10.1089/jpm.2011.0207.CrossRefPubMedPubMedCentral

54.

Warwick G, Mooney A, Russon L, Hardy R: Clinical practice guideline: planning, initiation and withdrawal of renal replacement therapy. 2014. Available from: https://renal.org/wp-content/uploads/2017/06/planning-initiation-finalf506a031181561659443ff000014d4d8.pdf

55.

Hussain JA, Mooney A, Russon L. Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease. Palliat Med. 2013 Oct;27(9):829–39. https://doi.org/10.1177/0269216313484380.CrossRefPubMed

56.

Murtagh FEM, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dialysis Transplant. 2007 Jul;22(7):1955–62. https://doi.org/10.1093/ndt/gfm153.CrossRef

57.

Woo K, Lok CE. New insights into Dialysis vascular access: what is the optimal vascular access type and timing of access creation in CKD and Dialysis patients? Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1487–94. https://doi.org/10.2215/CJN.02190216.CrossRefPubMedPubMedCentral

58.

Shrestha BM, Shrestha D, Kumar A, Shrestha A, Boyes SA, Wilkie ME. Advanced laparoscopic peritoneal Dialysis catheter insertion: systematic review and meta-analysis. Perit Dial Int. 2018 May;38(3):163–71. https://doi.org/10.3747/pdi.2017.00230.CrossRefPubMed

59.

Ranganathan D, John GT, Yeoh E, Williams N, O'Loughlin B, Han T, et al. A randomized controlled trial to determine the appropriate time to initiate peritoneal Dialysis after insertion of catheter (timely PD study). Perit Dial Int. 2017 Jul;37(4):420–8. https://doi.org/10.3747/pdi.2016.00066.CrossRefPubMed

60.

Crabtree JH, Shrestha BM, Chow K-M, Figueiredo AE, Povlsen JV, Wilkie M, et al. Creating and maintaining optimal peritoneal Dialysis access in the adult patient: 2019 update. Perit Dial Int. 2019 Sep;39(5):414–36. https://doi.org/10.3747/pdi.2018.00232.CrossRefPubMed

61.

Povlsen JV, Ivarsen P. How to start the late referred ESRD patient urgently on chronic APD. Nephrol Dialysis Transplant. 2006;21(Suppl 2):ii56–9.CrossRef

62.

Liu Y, Zhang L, Lin A, Ni Z, Qian J, Fang W. Impact of break-in period on the short-term outcomes of patients started on peritoneal dialysis. Perit Dial Int. 2014 Jan;34(1):49–56. https://doi.org/10.3747/pdi.2012.00293.CrossRefPubMedPubMedCentral

63.

Lobbedez T, Lecouf A, Ficheux M, Henri P, Hurault de Ligny B, Ryckelynck J-P. Is rapid initiation of peritoneal dialysis feasible in unplanned dialysis patients? A single-Centre experience. Nephrol Dial Transplant. 2008;23(10):3290–4. https://doi.org/10.1093/ndt/gfn213.CrossRefPubMed

64.

Koch M, Kohnle M, Trapp R, Haastert B, Rump LC, Aker S. Comparable outcome of acute unplanned peritoneal dialysis and haemodialysis. Nephrol Dial Transplant. 2012 Jan;27(1):375–80. https://doi.org/10.1093/ndt/gfr262.CrossRefPubMed

65.

Boissinot L, Landru I, Cardineau E, Zagdoun E, Ryckelycnk J-P, Lobbedez T. Is transition between peritoneal dialysis and hemodialysis really a gradual process? Perit Dial Int. 2013;33:391–7.CrossRef

66.

Chan C, Combes G, Davies S, Finkelstein F, Firanek C, Gomez R, et al. Transition between different renal replacement modalities: gaps in knowledge and care-the integrated research initiative. Perit Dial Int. 2019;39(1):4–12. https://doi.org/10.3747/pdi.2017.00242.CrossRefPubMed

67.

Streja E. Hospital readmission for the dialysis patient: who is (not) responsible? Kidney Int. 2017;92:788–90.CrossRef

Title: Commentary on the NICE guideline on renal replacement therapy and conservative management
Authors: Kunaal Kharbanda
Osasuyi Iyasere
Fergus Caskey
Matko Marlais
Sandip Mitra
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Peritoneal Dialysis
Published in: BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-021-02461-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Please log in to get access to this content

Other articles of this Issue 1/2021

End-stage kidney disease and rationing of kidney replacement therapy in the free state province, South Africa: a retrospective study

Correction to: Hemolytic uremic syndrome caused by sea anemone sting: a case report

Remnant renal volume can predict prognosis of remnant renal function in kidney transplantation donors: a prospective observational study

Is health-related quality of life associated with adequacy of hemodialysis in chronic kidney disease patients?

Video as an alternative to in-person consultations in outpatient renal transplant recipient follow-up: a qualitative study

First and second morning spot urine protein measurements for the assessment of proteinuria: a diagnostic accuracy study in kidney transplant recipients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage